



National Based, Retrospective Study on the Evaluation of Clinical, Laboratory, and Imaging Research of Tuberous Sclerosis Cases

*Hüseyin Per, * Mehmet Canpolat, *Ayten Güleç, Esra Serdaroğlu, Yavuz Atas, İlknur Erol, Aydan Değerliyurt, Betül Kılıç, Meltem Çobanoğulları Direk, Gökçen Öz Tunçer, Selcan Öztürk, Kürşat Bora Çarman, Ebru Arhan, Seda Kanmaz, Yasemin Ozkale, Meryem Hilal Altaş, Emek Uyur Yalçın, Uluç Yiş, Serdal Güngör, Dilşad Türkdoğan, Ali Cansu, Ayşe Tosun, Bülent Ünay, Yasemin Topçu, Türkan Uygur Şahin, Nihal Olgaç Dünder, Aslıhan Akdamar Kaya, Şeyda Besen, Ömer Karaca, Sevinç Keskin Keçecioglu, Tuğba Hirfanoğlu, Hepsen Mine Serin, Kürşad Aydın, Gülbahar Kurt Bayır, Coşkun Yazar, Sibgatullah Ali Orak, Nilufer Eldeş Hacıhafızoglu, Ayşe Semra Hız, Bilge Özgör, Burcu Karakayalı, Nihal Yıldız, Çisil Çerçi, Hülya İnce, Rojan İpek, Dilek Çavuşoğlu, Canan Üstün, Çetin Okuyaz, Seçil Oktay, Ayşegül Danış, *Hakan Gümüş, Ayşe Serdaroğlu, Turkish Tuberous Sclerosis Study Group

Erciyes University Faculty of Medicine, Department of Pediatric Neurology



INTRODUCTION

The aim of this study is to evaluate clinical, laboratory, and imaging studies of tuberous sclerosis complex (TSC) cases at the national level in Turkey.

Results Table 1

Signs and Symptoms	N	% of All	Age at onset/ Mean ±SD	Median (min-max)	p
The first application to the hospital	774	100	42.6±49.4	18/6-72	<0.01
Gender(F/M)	355/419	45.8/54.2	-		
Application Complaint					
Seizure	544	70.2			
Skin Signs	90	11.6			
Learning Difficulty	4	0.51			
Psychiatric Symptoms	2	0.25			
The Others(rhabdomyoma/Incidentally ect)	134	17.3			
Neurological findings	650	83.97			
Epilepsy	640	82.68			
West Syndrome (*99 cases disappeared)	223	28.81	7.5±8.5 *Disappear 24.5±25.2	6/3-8.2 *Disappear 14/7-144	<0.01
Focal Seizures* (*92 cases disappeared)	374	48.3	25.9±34.7 *Disappear 68.3±54.9	12/0-204 *Disappear 60/0-245	<0.01
Generalized Seizures* (*93 cases disappeared)	379	48.9	26.6±37.6 *Disappear 47±48	11/0-240 *Disappear 24/1-216	<0.01
LGS* (*one case disappeared)	43	5.5	50.3±30.4 *Disappear 66	41/11-120	-

Turkish Tuberous Sclerosis Study Group

Ahmet Öztürk, Hamit Acer, Sefer Kumandaş, Sanem Keskin Yılmaz, Leman Tekin Olgun, Esra Özpinar, Burçin Gönüllü Polat, Seren Aydın, Arife Derda Yücel Şen, Derya Güder, Ayşen Gök, Meral Karadağ, Pınar Gençpinar, Elif Didinmez Taşkırdı, Mesut Güngör, Murat Özkale, Muzaffer Polat, Elif Pelin Öncel, Fatma Hancı, Hasan Tekgül

MATERIALS & METHODS

Patients who were diagnosed with TSC between January 2010 to January 2022 through a 23-centered retrospective study in Turkey and were followed up for at least 3 months, presenting complaints, demographic data, radiological findings, specific organ involvement, medical and surgical treatment options, response to treatment and follow-up.

Results Table 2

Signs and Symptoms	N	% of All	Age at onset/ Mean ±SD	Median (min-max)	p
TAND	651	90.4			
Anxiety	81	10.4			
Intellectual Disability	642	82.9	-		
Border zone/ mild	489	63.1	-		
Moderate	98	12.6	-		
Severe	55	7.1	-		
Autism Spectrum Disorder	126	16.2	30.8±24.3	36(24-101)	<0.01
ADHD	119	15.3	58.2±28.8	54.5(48-160)	0.09
Mood Disorders	44	5.6	85.5±64.9	60(24-216)	0.06
Depression	12	1.55	-	-	
Decreased Self Esteem	8	1.03	-		
Other(disartri,aggressive excited, puberty and adjustment disorder	19	2.4	-		
MRI used	761	98.3			
Cortical Tubers /Hamartomas	652	84.2	38.46±48	13.5/5-60.5	
SENs	505	65.3	39.9±47.9	16/6-60	
Linear White matter Lesions/ Heterotopia	114	14.7	51±51.2	30(0-216)	<0.01
SEGA	110	14.2	67.9±59.8	60/12.2-120	
	57	7.3	-	-	
Hypomyelination areas					

RESULTS

Totally 774 patients were included, newborns to 18 years, mean age at onset was 42.6 months with 74 months follow-up time. 70.2% presented with epilepsy, %11.6 with only skin lesions, 0.3% with learning problems, and %17.9 with other problems.

Hypomelanotic macule and ash leaf were detected in the most of skin lesions (631- 81.5 % of all patients) then respectively comes anjiofibromas, shagreen patches, confetti-like macules, periungual fibroids, molluscum fibrosum and other fibrous lesions. Renal Angiomyolipomas was detected about 32% and 185/250 of them were bilateral; Renal cysts were only at 14.8% and frequently unilateral(85/115)

82% of total cases (n:640) had epilepsy with a mean onset of 22 months and 213/640 were followed up with West syndrome. Intellectual disability was 87.3% (40.1% borderline, 25.5% mild, 13.4% moderate, 6% severe and 1.4% very severe). Autism spectrum disorder 14 % (100/714) and attention deficit hyperactivity disorder 14.1%(101/714) were not rare.

There was a positive and statistically significant correlation between age at onset and beginning age of epilepsy r=0.47,p<0,01

Also beginning age of SENs –SEGA and Cortical Tubers with beginning age of epilepsy had a positive and statistically significant correlation (respectively r:0.62-0.59-0.62, p<0,01)There was negative correlation between mTOR dose and Vigabatrin dose (r:-0.75,p:0,05) and mTOR dose with Vigabatrin using the time(r:-0,64, p:0,082)

Between Vigabatrin dose and vigabatrin using time was also negative correlated.(r=-0.149, p:0,033)

Results Table 3

Signs and Symptoms	N	% of All	Mean ±SD	Median (min-max)
Treatment	658	85	-	-
Antiepileptic (VPA/LEV/TPX/CM Z vs)	645	83.3	-	-
Vigabatrin	399	51.5	Time:30.1±30.6 Dose:94.3±33.5	Time:24 (8-36) Dose:100 (70-120)
Everolimus	91	11.7	-	-
Antipsychotic	60	7.7	-	-
ACTH	58	7.5	-	-
Sirolimus	42	5.4	-	-
Surgery	46	5.9	-	-
Piridoksin	19	2.4	-	-
mTor*	*39	5	Time:26±23.6 Dose:3±1.15	Time: 24/2-96 Dose: 2.5/2-5
mTor*Dose(mg/m ²)				
Following patients	613	79.2	-	-
Follow-up time *	754		74±60.72	60/1-390
Mortality	31	4	-	-

CONCLUSIONS

TSC is a complex disorder that is associated with many organs and systems. Skin examination is important to suspect TSC. In this study, it was observed that the frequency of cranial involvement at the time of admission was high and the first admission was after serious complaints such as seizures. For this reason, prospective studies with large case series and epidemiology studies are needed.

The retrospective study had some difficulties to reach some records(for example time to the beginning of signs and symptoms and the resolution time, drugs dose and duration of use, the dimensions of lesions before and after the surgery)